Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study
Abstract Background The intricate and varied clinical presentations of systemic sclerosis (SSc) pose significant challenges for treatment. While several studies have investigated the therapeutic potential of mesenchymal stem cell transplantation (MSCT), the clarity of its long-term outcomes for SSc...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-025-04237-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850039617406894080 |
|---|---|
| author | Wenyi Yuan Mian Liu Dapeng Yang Yirui Shi Zhikang Wang Xuan Cao Jun Liang Linyu Geng Huayong Zhang Xuebing Feng Ziyi Jin Dandan Wang Lingyun Sun |
| author_facet | Wenyi Yuan Mian Liu Dapeng Yang Yirui Shi Zhikang Wang Xuan Cao Jun Liang Linyu Geng Huayong Zhang Xuebing Feng Ziyi Jin Dandan Wang Lingyun Sun |
| author_sort | Wenyi Yuan |
| collection | DOAJ |
| description | Abstract Background The intricate and varied clinical presentations of systemic sclerosis (SSc) pose significant challenges for treatment. While several studies have investigated the therapeutic potential of mesenchymal stem cell transplantation (MSCT), the clarity of its long-term outcomes for SSc patients is still lacking. Methods Data on MSCT were extracted from the medical records of inpatients at Nanjing Drum Tower Hospital between January 2013 and December 2022. Additionally, Baseline characteristics and survival outcomes were ascertained from medical records and telephone follow-up. Propensity score matching (PSM) was employed to equalize the baseline characteristics of the patient groups, while survival analysis and multivariate Cox regression assessed the relationship between received MSCT and all-cause mortality and disease-specific survival rates in SSc patients. Results Of the 333 hospitalized SSc patients, 113 patients underwent MSCT. The log-rank test revealed significantly higher survival rates in the MSCT group compared to the control group (10-year survival rate 89.4% vs. 73.4%, P = 0.002). In the PSM cohort, receiving MSCT significantly reduced mortality (10-year survival 88.0% vs. 79.9%, P = 0.032). Multivariate Cox regression analysis indicated that MSCT was linked to a reduced mortality risk during the follow-up period (HR 0.38, 95% CI 0.19–0.75, P = 0.005). This finding was further confirmed in the matched cohort (HR 0.38, 95% CI 0.18–0.82, P = 0.014). Subgroup analyses revealed that treated with MSCT was correlated with reduced mortality in patients of various demographics, including younger age at diagnosis (≤ 47 years), female, diffuse cutaneous systemic sclerosis (dcSSc) subtype, concurrent arthritis, pulmonary arterial hypertension (PAH), and interstitial lung disease (ILD). Conclusion MSCT significantly enhances the survival rate of patients with SSc, with outcomes related to the age at diagnosis. MSCT is particularly indicated for patients with comorbid conditions, including PAH, ILD, digital ulcers, and arthritis, as well as those with severe disease presentations associated with the dcSSc subtype. |
| format | Article |
| id | doaj-art-040102f610ce49d1b29df50a3b0ea9b3 |
| institution | DOAJ |
| issn | 1757-6512 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-040102f610ce49d1b29df50a3b0ea9b32025-08-20T02:56:16ZengBMCStem Cell Research & Therapy1757-65122025-03-0116111210.1186/s13287-025-04237-1Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort studyWenyi Yuan0Mian Liu1Dapeng Yang2Yirui Shi3Zhikang Wang4Xuan Cao5Jun Liang6Linyu Geng7Huayong Zhang8Xuebing Feng9Ziyi Jin10Dandan Wang11Lingyun Sun12Department of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Xuzhou Medical UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing UniversityDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineDepartment of Rheumatology and Immunology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese MedicineAbstract Background The intricate and varied clinical presentations of systemic sclerosis (SSc) pose significant challenges for treatment. While several studies have investigated the therapeutic potential of mesenchymal stem cell transplantation (MSCT), the clarity of its long-term outcomes for SSc patients is still lacking. Methods Data on MSCT were extracted from the medical records of inpatients at Nanjing Drum Tower Hospital between January 2013 and December 2022. Additionally, Baseline characteristics and survival outcomes were ascertained from medical records and telephone follow-up. Propensity score matching (PSM) was employed to equalize the baseline characteristics of the patient groups, while survival analysis and multivariate Cox regression assessed the relationship between received MSCT and all-cause mortality and disease-specific survival rates in SSc patients. Results Of the 333 hospitalized SSc patients, 113 patients underwent MSCT. The log-rank test revealed significantly higher survival rates in the MSCT group compared to the control group (10-year survival rate 89.4% vs. 73.4%, P = 0.002). In the PSM cohort, receiving MSCT significantly reduced mortality (10-year survival 88.0% vs. 79.9%, P = 0.032). Multivariate Cox regression analysis indicated that MSCT was linked to a reduced mortality risk during the follow-up period (HR 0.38, 95% CI 0.19–0.75, P = 0.005). This finding was further confirmed in the matched cohort (HR 0.38, 95% CI 0.18–0.82, P = 0.014). Subgroup analyses revealed that treated with MSCT was correlated with reduced mortality in patients of various demographics, including younger age at diagnosis (≤ 47 years), female, diffuse cutaneous systemic sclerosis (dcSSc) subtype, concurrent arthritis, pulmonary arterial hypertension (PAH), and interstitial lung disease (ILD). Conclusion MSCT significantly enhances the survival rate of patients with SSc, with outcomes related to the age at diagnosis. MSCT is particularly indicated for patients with comorbid conditions, including PAH, ILD, digital ulcers, and arthritis, as well as those with severe disease presentations associated with the dcSSc subtype.https://doi.org/10.1186/s13287-025-04237-1Systemic sclerosisMesenchymal stem cellsTreatmentMortality |
| spellingShingle | Wenyi Yuan Mian Liu Dapeng Yang Yirui Shi Zhikang Wang Xuan Cao Jun Liang Linyu Geng Huayong Zhang Xuebing Feng Ziyi Jin Dandan Wang Lingyun Sun Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study Stem Cell Research & Therapy Systemic sclerosis Mesenchymal stem cells Treatment Mortality |
| title | Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study |
| title_full | Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study |
| title_fullStr | Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study |
| title_full_unstemmed | Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study |
| title_short | Improvement in long-term survival with mesenchymal stem cell transplantation in systemic sclerosis patients: a propensity score-matched cohort study |
| title_sort | improvement in long term survival with mesenchymal stem cell transplantation in systemic sclerosis patients a propensity score matched cohort study |
| topic | Systemic sclerosis Mesenchymal stem cells Treatment Mortality |
| url | https://doi.org/10.1186/s13287-025-04237-1 |
| work_keys_str_mv | AT wenyiyuan improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT mianliu improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT dapengyang improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT yiruishi improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT zhikangwang improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT xuancao improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT junliang improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT linyugeng improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT huayongzhang improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT xuebingfeng improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT ziyijin improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT dandanwang improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy AT lingyunsun improvementinlongtermsurvivalwithmesenchymalstemcelltransplantationinsystemicsclerosispatientsapropensityscorematchedcohortstudy |